Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Applied Therapeutics Inc
APLTCurrent price
5.2 USD
-0.08 USD (-1.52%)
Last closed
5.24 USD
Company
www.appliedtherapeutics.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
587 332 352 USD
Yield for 12 month
+246.67 %
1Y
3Y
5Y
10Y
15Y
APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. Address: 545 Fifth Avenue, New York, NY, United States, 10017
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11.4 USDP/E ratio
–Dividend Yield
–Current Year
+9 993 000 USD
Last Year
+10 660 000 USD
Current Quarter
+190 000 USD
Last Quarter
-667 000 USD
Current Year
+9 640 000 USD
Last Year
-441 000 USD
Current Quarter
+71 000 USD
Last Quarter
-1 014 000 USD
Key Figures APLT
1 year
3 years
5 years
10 years
EBITDA
-74 768 496 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-51.57 %
PEG Ratio
–
Return On Equity TTM
-612.33 %
Wall Street Target Price
11.4 USD
Revenue TTM
-477 000 USD
Book Value
0.59 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-98.2 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.91 USD
Diluted Eps TTM
-1.91 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics APLT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History APLT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation APLT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
49.7603
Price Sales TTM
54.676
Enterprise Value EBITDA
-7.7477
Price Book MRQ
4.8902
Financials APLT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators APLT
For 52 weeks
1.18 USD
9.39 USD
50 Day MA
4.68 USD
Shares Short Prior Month
5 753 695
200 Day MA
3.99 USD
Short Ratio
4.13
Shares Short
6 316 963
Short Percent
6.18 %
BeatStart